Complement System
The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.
The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.
All Product Categories
-
Complement System Inhibitors
(133)
View all products
-
Complement System Agonists
(13)
View all products
-
Complement System Antagonists
(21)
View all products
-
Complement System Activators
(7)
View all products
-
Complement System Modulator
(1)
View all products
-
Complement System Controls
(2)
View all products
-
Complement System Ligands
(3)
View all products
-
Complement System Proteins
(113)
View all products
-
Complement System 관련 제품 (211)
-
Recombinant Proteins (113)
-
Antibodies (7)
-
Aristolone
0 ImagesAristolone is a sesquiterpene that can be isolated from Aristolochia debilis, Rosmarinus officinalis and Ficus Auriculata. Aristolone in Ara Fruit can be used as a prediction of apoptosis in HeLa cells. Aristolone inhibits the C1 complement component. Aristolone produces cytotoxicity effects on cells. Aristolone has anticancer properties and can be studied in research for cervical cancer.
-
Cemdisiran sodium
0 ImagesCat. No.: HY-145720ASynonyms: ALN-CC5 sodiumCemdisiran sodium is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.
-
3-Phenoxybenzaldehyde
0 ImagesSynonyms: m-Phenoxybenzaldehyde3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity.
-
PIC1 PA
0 ImagesPIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM.
-
Compstatin TFA
0 ImagesCat. No.: HY-P1036APurity: 99.11%Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
-
Ruxoprubart
0 ImagesCat. No.: HY-P991022CAS No.: 2842046-67-5Synonyms: NM8074Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy.
-
Complement C1s-IN-1
0 ImagesCat. No.: HY-149278CAS No.: 3033831-40-9Complement C1s-IN-1 is a potent, selective, orally active and cross the blood-brain barrier C1s inhibitor with an IC50 value of 36 nM.
-
Zaltenibart
0 ImagesSynonyms: OMS906Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria.
-
Isocyclosporin A
0 ImagesIsocyclosporin A is a degradation product of the immunosuppressant Cyclosporin A.
-
Avacincaptad pegol
0 ImagesCat. No.: HY-148457CAS No.: 1613641-69-2Synonyms: IzervayAvacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA.
-
Dexamethasone-d5
0 ImagesSynonyms: Hexadecadrol-d5; Prednisolone F-d5Dexamethasone-d5 is the deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
-
NRP1 antagonist 2
0 ImagesNRP1 antagonist 2 (Compound 1) is an NRP1 antagonist.
-
Izicopan
0 ImagesCat. No.: HY-177094CAS No.: 2489430-53-5Synonyms: INF056Izicopan (INF056) is a complement factor C5a receptor antagonist. Izicopan inhibits C5a-induced calcium mobilization with an IC50 of 10-100 nM.
-
Lampalizumab
0 ImagesSynonyms: RG 7417; TNX 234; Anti-CFD Recombinant AntibodyLampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.
-
Dexamethasone-d3-1
0 ImagesCat. No.: HY-14648S5Purity: 98.02%Synonyms: Hexadecadrol-d3-1; Prednisolone F-d3-1Dexamethasone-d3-1 (Hexadecadrol-d3-1; Prednisolone F-d3-1) is a deuterium labeled Dexamethasone (HY-14648). Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
-
C1q Protein (rat)
0 ImagesCat. No.: HY-NP0194CC1q Protein (rat) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rat) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rat) can be used for the research of mutiple disease.
